本帖最后由 老马 于 2012-1-13 21:20 编辑 7 ~/ }, w l9 ~0 k
5 M' o# m! s: S2 F8 ?( p爱必妥和阿瓦斯丁的比较
; ^6 r a* K8 U
3 }& S% C q7 a2 Q8 {
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/' d" J0 w% s/ F3 z2 B
/ J/ N/ o" N- `% X( T( F& H& b
1 c/ j& ?; {( whttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/9 W( S, Y4 d. g9 L
==================================================
2 n9 l# R6 j s; A: L* P2 E0 y. ]Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)1 a. u4 [1 _9 h4 e
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
" j8 m: c6 G0 T, k9 l: x$ WResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.7 a& M9 i8 o8 {( ]
|